Drug Profile
CNS 242
Alternative Names: CNS-242Latest Information Update: 06 Apr 2021
Price :
$50
*
At a glance
- Originator Nippon Suisan Kaisha
- Class Antigouts; Uricosurics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout; Hyperuricaemia
Most Recent Events
- 06 Apr 2021 Phase II development in Hyperuricaemia is still ongoing in United Kingdom (PO) (EudraCT2005-001143-31)
- 30 Jul 2020 Nippon Suisan Kaisha completes a phase II trial in Hyperuricaemia and Gout in United Kingdom (PO) (EudraCT2005-001143-31)
- 22 Jan 2019 Nippon Suisan Kaisha has patents pending for CNS 242 in Japan and other countries worldwide